When a firm is developing a novel investigative product (IP) based on its effect on a particular molecular target or on its effect on a particular biomarker — rather than on its effect on a specific indication — there comes a point at which that developer needs to make decisions about directing and prioritizing its efforts. To make well-informed strategic decisions about how best to focus potentially divergent development efforts, decisionmakers need insight into all these matters. This is where a strategic portfolio review can play an important role in a development program. Read our white paper to learn more.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
